Unicycive Therapeutics Inc
UNCY6.340USD
+5.672+849.81%
收盤 06/20, 16:00（美東）報價延遲15分鐘
759.21M總市值
虧損本益比TTM
關於 Unicycive Therapeutics Inc 公司
Unicycive Therapeutics, Inc. 是一家生物技術公司，正在開發某些疾病的治療方法。其項目專注於腎臟疾病，這是一個有可能帶來醫療益處的領域。其開發項目專注於兩種新型療法：Oxylanthanum Carbonate 和 UNI 494。Oxylanthanum Carbonate 是一種新型的試驗性磷酸鹽結合劑，正在開發用於治療透析慢性腎臟病患者的高磷血癥。UNI-494 是一種受專利保護的新化學實體，正在臨牀開發中，用於治療與急性腎損傷相關的疾病。Oxylanthanum Carbonate 和 UNI 494 最初由 Spectrum Pharmaceuticals (Spectrum) 和 Sphaera Pharma 開發並分別獲得其許可。
公司簡介
公司代碼UNCY
公司名稱Unicycive Therapeutics Inc
上市日期Jun 17, 2021
成立日期2016
CEODr. Shalabh Gupta, M.D.
員工數量22
證券類型Ordinary Share
年結日Jun 17
公司地址4300 El Camino Real, Suite 210
城市LOS ALTOS
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94022
電話16503840642
網址https://unicycive.com/
公司代碼UNCY
上市日期Jun 17, 2021
成立日期2016
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月15日 週四
更新時間: 5月15日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Vivo Capital, LLC
0.94%
Great Point Partners, LLC
0.91%
Octagon Capital Advisors LP
0.83%
Nantahala Capital Management, LLC
0.78%
Gupta (Shalabh K)
0.50%
Other
96.04%
持股股東
持股股東
佔比
Vivo Capital, LLC
0.94%
Great Point Partners, LLC
0.91%
Octagon Capital Advisors LP
0.83%
Nantahala Capital Management, LLC
0.78%
Gupta (Shalabh K)
0.50%
Other
96.04%
股東類型
持股股東
佔比
Hedge Fund
3.68%
Venture Capital
1.37%
Individual Investor
0.52%
Investment Advisor/Hedge Fund
0.17%
Investment Advisor
0.01%
Research Firm
0.01%
Other
94.23%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
61
68.99M
57.19%
+435.46K
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
2023Q1
38
9.94M
65.95%
+1.31M
2022Q4
33
9.05M
60.10%
+325.03K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Vivo Capital, LLC
9.97M
8.33%
--
--
Dec 31, 2024
Great Point Partners, LLC
10.98M
9.17%
+2.42M
+28.29%
Dec 31, 2024
Octagon Capital Advisors LP
10.00M
8.35%
+1.44M
+16.84%
Dec 31, 2024
Nantahala Capital Management, LLC
10.39M
8.68%
+7.57M
+268.46%
Dec 31, 2024
Gupta (Shalabh K)
5.97M
4.99%
--
--
Apr 25, 2024
Logos Global Management LP
5.08M
4.24%
--
--
Dec 31, 2024
Walleye Capital LLC
5.00M
4.18%
--
--
Dec 31, 2024
SilverArc Capital Management, LLC
2.49M
2.08%
-1.51M
-37.83%
Dec 31, 2024
Acuta Capital Partners, LLC
2.30M
1.92%
+323.80K
+16.36%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
